The pursuit of outperformance leads many investors to carefully choose individual stocks. Picking the right ones can be a game-changer for growing your wealth.
The closing price of Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) was $12.09 for the day, up 0.67% from the previous closing price of $12.01. In other words, the price has increased by $0.67 from its previous closing price. On the day, 2.71 million shares were traded. AUPH stock price reached its highest trading level at $12.315 during the session, while it also had its lowest trading level at $11.725.
Ratios:
Our analysis of AUPH’s different ratios will help us gain a deeper understanding of the company. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 5.05 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 17.24. For the most recent quarter (mrq), Quick Ratio is recorded 4.63 and its Current Ratio is at 5.23. In the meantime, Its Debt-to-Equity ratio is 0.24 whereas as Long-Term Debt/Eq ratio is at 0.19.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Aug 01 ’25 when TANG KEVIN bought 1,000,000 shares for $10.12 per share. The transaction valued at 10,120,000 led to the insider holds 11,029,500 shares of the business.
TANG KEVIN bought 200,000 shares of AUPH for $2,336,000 on Aug 05 ’25. The Director now owns 11,329,500 shares after completing the transaction at $11.68 per share. On Aug 04 ’25, another insider, TANG KEVIN, who serves as the Director of the company, bought 100,000 shares for $11.34 each. As a result, the insider paid 1,134,000 and bolstered with 11,129,500 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, AUPH now has a Market Capitalization of 1591406720 and an Enterprise Value of 1358186240. As of this moment, Aurinia’s Price-to-Earnings (P/E) ratio for their current fiscal year is 28.27, and their Forward P/E ratio for the next fiscal year is 15.87. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 0.15. For the stock, the TTM Price-to-Sale (P/S) ratio is 6.12 while its Price-to-Book (P/B) ratio in mrq is 4.78. Its current Enterprise Value per Revenue stands at 5.222 whereas that against EBITDA is 16.447.
Stock Price History:
The Beta on a monthly basis for AUPH is 1.27, which has changed by 0.93130994 over the last 52 weeks, in comparison to a change of 0.16461086 over the same period for the S&P500. Over the past 52 weeks, AUPH has reached a high of $12.10, while it has fallen to a 52-week low of $5.41. The 50-Day Moving Average of the stock is 34.19%, while the 200-Day Moving Average is calculated to be 43.73%.
Shares Statistics:
AUPH traded an average of 1.98M shares per day over the past three months and 3648960 shares per day over the past ten days. A total of 132.67M shares are outstanding, with a floating share count of 116.19M. Insiders hold about 11.73% of the company’s shares, while institutions hold 45.69% stake in the company. Shares short for AUPH as of 1753920000 were 9156638 with a Short Ratio of 4.62, compared to 1751241600 on 10015540. Therefore, it implies a Short% of Shares Outstanding of 9156638 and a Short% of Float of 7.62.
